Clark John A, Schulman Gerald, Golper Thomas A
Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA.
Clin J Am Soc Nephrol. 2008 May;3(3):736-42. doi: 10.2215/CJN.03460807. Epub 2008 Feb 13.
Patients who may benefit from sustained low-efficiency dialysis therapy are often at risk for bleeding. A safe and simple "regional" anticoagulation strategy would be beneficial. The modification of existing regional citrate anticoagulation protocols to typically performed 8-h sustained low-efficiency dialysis is necessary.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sustained low-efficiency dialysis was performed at blood and dialysate rates of 250 and 300 ml/min, respectively. The circuit was anticoagulated with 4% sodium citrate (citrate 136, sodium 408 mmol/L) and reversed with CaCl(2). Every 2 h, electrolytes, ionized circuit, and patient calcium were monitored during the first two versions. The second version differed by an increased infusion of CaCl(2) and lower infusion of citrate, both by 10%. The third version measured only laboratory values before and after sustained low-efficiency dialysis.
There were 41 treatments in the first iteration, 42 in the second, and 34 in the final iteration. All versions were titrated to maintain patient ionized calcium of 4.0 to 4.8 mg/dl (1.0 to 1.2 mmol/L) and the circuit ionized calcium between 0.8 and 1.6 mg/dl (0.2 and 0.4 mmol/L). The final protocol infusion was 31 mmol/h citrate and 41 mmol/h elemental calcium, which kept circuit and patient ionized calcium at targets. No unexpected metabolic complications occurred.
Compared with continuous renal replacement therapy, one must increase the calcium infusion because of the more efficient removal of the calcium citrate complex. Safe and effective regional citrate anticoagulation can be performed in 8-h sustained low-efficiency dialysis without metabolic complications with laboratory surveillance only before and after sustained low-efficiency dialysis treatment; however, certain safeguards are mandatory.
可能从持续性低效透析治疗中获益的患者常常有出血风险。一种安全且简单的“局部”抗凝策略会有益处。有必要对现有的局部枸橼酸盐抗凝方案进行调整,以用于通常进行的8小时持续性低效透析。
设计、场所、参与者与测量:分别以250和300毫升/分钟的血流速和透析液流速进行持续性低效透析。用4%枸橼酸钠(枸橼酸盐136,钠408毫摩尔/升)对体外循环进行抗凝,并使用氯化钙进行中和。在前两个版本中,每2小时监测电解质、体外循环离子化钙和患者血钙。第二个版本的不同之处在于氯化钙输注量增加10%,枸橼酸盐输注量降低10%。第三个版本仅在持续性低效透析前后测量实验室值。
第一次迭代有41次治疗,第二次有42次,最后一次迭代有34次。所有版本都进行了滴定,以维持患者离子化钙在4.0至4.8毫克/分升(1.0至1.2毫摩尔/升),体外循环离子化钙在0.8至1.6毫克/分升(0.2至 0.4毫摩尔/升)。最终方案输注量为枸橼酸盐31毫摩尔/小时,元素钙41毫摩尔/小时,这使体外循环和患者离子化钙维持在目标水平。未发生意外的代谢并发症。
与连续性肾脏替代治疗相比,由于枸橼酸钙复合物清除效率更高,必须增加钙的输注量。在8小时持续性低效透析中可以进行安全有效的局部枸橼酸盐抗凝,且仅在持续性低效透析治疗前后进行实验室监测时不会出现代谢并发症;然而,某些保障措施是必不可少的。